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Abstract
Congenital leukemia is rarely encountered in clinical practice, even in tertiary children's
hospitals. Leukemia may cause significant coagulopathy, putting the patient at risk of
intracranial hemorrhage. In this case, the authors present a female infant with a unique mixed
phenotypic congenital acute myeloid leukemia showing mixed-lineage leukemia (MLL)
rearrangement and severe coagulopathy resulting in a large subdural hematoma. Despite the
fatal outcome in this case, neurosurgical treatment of patients with acute myeloid leukemia
should be considered if coagulopathy and the clinical scenario allow.
Categories: Pediatrics, Neurosurgery, Oncology
Keywords: congenital leukemia, fetal leukemia, subdural hematoma, 11q23, mll rearrangement, 19p13.3
Introduction
Congenital leukemia, defined as leukemia diagnosed between birth and four weeks of life, is
diagnosed in 0.2 to 4.7 in 1 million births [1-2], with acute myeloid leukemia (AML) more
common than acute lymphoblastic leukemia (ALL) in the neonates [3-5]. In both congenital AML
and ALL, the most common genetic defects, found in more than half of congenital leukemias,
involve the rearrangement of the mixed-lineage leukemia (MLL) gene at chromosome 11q23 [6].
The prognosis remains poor [4, 7], with 23% and 26% survival in two large studies [3, 8]. Despite
this, other authors have reported patients with long-term survival or even spontaneous
remission with specific subtypes of acute leukemia [9–15]. Review of the literature revealed only
one patient with congenital leukemia with intraparenchymal hemorrhage and fatal outcome [16].
The authors present their experience with a large subdural hematoma that likely occurred in
utero secondary to congenital leukemia and profound coagulopathy.
Case Presentation
History and physical examination
The female infant was born at 36 weeks estimated gestational age to a 28-year-old Gravida 1
mother whose pregnancy had been uncomplicated until 34 weeks gestation at which point she
developed pre-term labor which subsequently resolved. The infant was delivered via Caesarean
section for fetal decelerations following the spontaneous onset of labor. Apgar scores were 5 and
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5 at 1 and 5 minutes of life, respectively. The infant was intubated shortly after birth for 
respiratory distress. Initial examination of the skin was significant for a diffuse, non-blanching,
bluish-red, macular rash with some palpable areas and multiple petechiae. The abdomen was full
and somewhat distended with marked hepatosplenomegaly. The anterior fontanelle was slightly
full and all cranial sutures were well-approximated. The pupils were minimally anisocoric (4 mm
on the right, minimally reactive; 2 mm on the left, trace reactive). There was decreased
spontaneous movement of the left upper and lower extremities with associated decreased tone
throughout these extremities.
Laboratory and pathologic evaluation
Initial laboratory studies demonstrated a white blood cell (WBC) count of 188,000 cells/cumm
with 70% blasts, a hemoglobin of 9.2 g/dl, a platelet count of 110,000 cells/cumm, a partial
thromboplastin time of 58.9 seconds, a prothrombin time of 65.1 seconds, and an international
normalized ratio of 7.7. The patient showed laboratory findings concerning for tumor lysis
syndrome, including elevated lactate dehydrogenase (> 76,000 IU/cumm; normal 130-700
IU/cumm), and uric acid (9.1 mg/dl; normal 2.0-6.0 mg/dl).
Examination of the peripheral blood smear and corresponding cytospin specimens showed
blasts, the majority of which resembled monoblasts or promonocytes (Figure 1A). Cytochemical
studies showed that a subset of blasts were positive for myeloperoxidase (MPO) and showed a
strong diffuse positivity for alpha-naphthyl butyrate esterase (NBE) (Figure 1B, 1C). Flow
cytometry showed the presence of an acute mixed phenotypic leukemia with 62% of events
within the myeloid gate, and 19% of events within the monocytic gate. Cells falling within the
myeloid gate showed coexpression of CD56, CD64, HLA-DR, TdT, and CD5 (partial). Cells falling
within the monocytic gate showed coexpression of HLA-DR, CD13, CD14, CD56, and CD64. A
pathologic diagnosis of AML with monocytic differentiation was given, and correlation with
cytogenetic studies was recommended.
FIGURE 1: Peripheral blood smear and corresponding cytospin Preparation.
Cytospin preparation (A) from the patient's peripheral blood smear shows the presence of
malignant cells as described in the text. Cytochemical staining of the peripheral blood smear
shows a subset of cells with MPO positivity (B) and strong diffuse positivity for NBE (C) [100x
objective].
Subsequent cytogenetic analysis demonstrated a karyotype of 46,XX,t(11;19)(q23;p13.3) in 20 of
20 analyzed metaphases. MLL gene rearrangement was confirmed by FISH, and there was no
evidence of PML/RARA, AML1/ETO, or CBFB rearrangements (Figure 2A and B). No evidence of
trisomy 8, trisomy 21, deletion/monosomy of 5q, or deletion/monosomy of 7q was detected. In
addition, mitogen-stimulated lymphocyte culture showed no germline chromosomal
abnormalities, consistent with chromosomal rearrangement. The observed translocation
[t(11;19)(q23;p13.3)] was thought to be an MLL to ENL/MLLT-1 fusion. An additional
chromosomal microarray analysis performed on peripheral blood was abnormal and showed a
~533Kb de novo interstitial deletion on the short arm of chromosome 19 (19p13.11) with a more
complex translocation (Figure 2C). Placental pathology showed evidence of abnormal fetal
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myeloid cells, but no other histopathologic abnormality. Bone marrow biopsy was deferred due
to severe coagulopathy.
FIGURE 2: Flourescence in-situ hybridization reveals complex MLL rearrangement.
A and B) 5' (green) and 3' (red) probes for MLL reveal a translocation of MLL with 5' portion on
chromosome 11 and 3' on chromosome 19. C) Probes for chromosome 19 (green and red - p and
q termini, respectively) reveal a more complex rearrangement or insertion has occurred.
Imaging
Head ultrasound performed at 15 hours of life identified a 5.8 x 3.9 cm mixed density, echogenic
lesion within the right middle cranial fossa (Figure 3). Ultrasound findings were consistent with
an extra-axial fluid collection, likely subdural hematoma, but underlying chloroma versus
vascular malformation could not be excluded. The ultrasound appearance suggested a large
extra-axial hemorrhage of varying age, though exact dating was not possible. The patient
subsequently underwent brain magnetic resonance imaging (MRI) at 21 hours of life for further
characterization (Figures 4-6). MRI confirmed the nature of the large right middle cranial fossa
lesion as a mixed intensity subdural hematoma with significant susceptibility artifact and
identified smaller left temporal and right cerebellar subdural hematomas. T2 imaging revealed a
fluid-fluid level with both hyper- and hypointense areas, suggestive of both acute and subacute
hemorrhage (Figure 4). MRI also identified an uncal herniation with multifocal areas of diffusion
restriction consistent with cerebral ischemia secondary to vascular compression and
microvascular emboli. Entrapment of the left lateral ventricle was also noted. Diffuse
enhancement of the leptomeninges was noted after contrast administration. 
FIGURE 3: Coronal views of head ultrasound on Day of Life 2.
Coronal views from posterior (A) to anterior (F) showing a large right-sided extra-axial hematoma.
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FIGURE 4: MRI of the brain - T1 with contrast and T2 axial views.
T1 with contrast (A-C) and T2 (D-F) axial views characterizing the subdural hematoma.
FIGURE 5: MRI of the brain – T1 coronal views and susceptibility-weighted imaging.
T1 coronal (A-C) and susceptibility-weighted imaging (D-F) views characterizing the subdural
hematoma.
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FIGURE 6: MRI of the brain – Diffusion and apparent diffusion coefficient imaging.
Diffusion (A-C) and apparent diffusion coefficient (D-F) axial views characterizing the subdural
hematoma.
Treatment
The infant underwent serial exchange transfusions for management of hyperleukocytosis and
received rasburicase® for tumor lysis syndrome. Once coagulation status permitted, the large
right middle cranial fossa subdural hematoma was tapped through a patent right coronal suture.
After a multidisciplinary discussion, including Neonatology, Neurosurgery,
Hematology/Oncology and Neurology, the parents were counseled regarding the treatment
options, including palliative neurosurgical interventions and aggressive chemotherapy in the
setting of an overall grim prognosis. Ultimately, the patient’s family decided to redirect care
toward comfort measures and the patient passed peacefully on Day of Life 4. 
Post-mortem evaluation
Post-mortem evaluation confirmed the radiographic findings and showed the presence of a right
middle cranial fossa hematoma involving not only the subdural space but also extending into the
subarachnoid space and involving the parenchymal surface (Figure 7A). There was midline shift,
compression of the right lateral ventricle, and mild expansion of the left lateral ventricle.
Parenchyma adjacent to the hematoma was soft, dusky colored, and disrupted. Multifocal
infarction was also present, particularly prominent in the head of the left caudate nucleus. In
addition, gross findings of a transtentorial herniation, including anterior-posterior elongation of
the midbrain and rostral pons, were present.
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FIGURE 7: Post-mortem examination of the central nervous system.
A) This coronal section reveals right-sided subdural hematoma, well-demarcated from the
underlying parenchyma in most areas. Intraparenchymal hemorrhage is notable within the left
caudate. Significant right-to-left midline shift is present. Photomicrograph demonstrating
intravascular and perivascular involvement of the central nervous system by malignant cells
using 20x objective [hematoxylin and eosin (B), MPO (C), and CD43 (D)].
Histological examination of the central nervous system showed intravascular, perivascular, and
leptomeningeal involvement by malignant-appearing mononuclear cells with hematopoietic
features (Figure 7B). Mitoses were numerous (atypical mitoses were also identified), and many of
the cells showed karyorrhexis. The cells showed strong myeloperoxidase (Figure 7C) and CD43
(Figure 7D) positivity, and were consistent with the diagnosis of AML established by
hematopathological and cytogenetic analysis.
In addition to the CNS findings, the post-mortem examination showed the extensive
involvement of multiple organ systems by AML blasts, many of which showed features of
vascular/peri-vascular spread. Sections of rash-involved skin showed diffuse dermal
involvement. Corresponding to the clinical finding of hepatosplenomegaly, the liver showed
diffuse sinusoidal involvement by neoplastic cells with few remaining cords present and splenic
red pulp was extensively involved and the spleen also showed extramedullary
hematopoiesis. Neoplastic cells involved the pleural surfaces and the submucosa of the upper
respiratory tract. The lungs showed neoplastic cells around bronchovascular bundles in the
interstitium. There was full thickness involvement of the wall of the esophagus, stomach, and
small and large intestines. In addition, blasts were present within sections of the: kidneys, heart,
thymus, pancreas, spleen, pituitary, lymph nodes, adrenals, uterus, and ovaries. Bone marrow
showed near 100% cellularity and was comprised predominantly of blasts.
The patient's placenta showed a maturation of chorionic villi consistent with the patient's
estimated gestational age and was of an appropriate weight. The umbilical cord was three-
vesseled, and fetal membranes were non-inflamed. There were no findings to suggest the
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presence of a TORCH agent. However, fetal blood showed the presence of immature myeloid
cells, consistent with AML blasts.   
After the patient expired, verbal consent was obtained from the parents for public discussion of
the patient's case. This case has been presented as a case review in NeoReviews as a neonatology
case review, but the full cytogenetic and pathological details were not described in detail.
Discussion
Congenital AML is a rare disorder that characteristically presents with leukemia cutis, an
infiltration of neoplastic leukocytes and their precursors into the dermis (blueberry muffin rash),
and hepatosplenomegaly [3]. Here, we present a case of a neonate with the classic findings of
congenital AML, in addition to an abnormal neurologic examination and coagulopathy. A large
middle fossa subdural hematoma caused severe compression of the diencephalon and brainstem,
ultimately leading to the patient's death despite attempted drainage.
Diagnostic workup showed an AML with monocytic features and a unique translocation, t(11;19)
(q23;p13.3), apparently resulting in fusion of MLL with ENL/MLLT-1. This translocation has been
previously reported to occur in both congenital AML and ALL [17]. Studies examining the
association between this specific translocation and leukemia have found generally poor survival
with infants faring worse than older children and adults. However, patient outcomes vary by age
and immunophenotype, and careful clinicopathological correlation is necessary for appropriate
patient management [18].
The MLL gene serves as an upstream regulator of homeobox genes, and MLL gene
rearrangements are believed to induce leukemia by altering normal homeobox gene expression in
hematopoiesis [19-20]. The in-utero development of congenital leukemia has been shown in
multiple studies, including concordant leukemia in twins, retrospective analysis of neonatal
blood spots, examination of cord blood, and examination of fetal death [21-22].
Intervention on neonatal subdural hematoma may involve craniotomy, drain placement,
percutaneous drainage, or subdural shunting procedure. In this case, only percutaneous drainage
was felt to be safe after the appropriate hematologic correction had been instituted. Additional
invasive procedures were discussed with the family but were not pursued. In one review of non-
Down syndrome neonates with leukemia, the overall three-year survival rate was 26%, with a
generally more favorable prognosis associated with AML versus ALL [4]. Thus, should clinical
circumstances allow, neurosurgical intervention in this patient population is appropriate.
Conclusions
Neonatal leukemia is a rare disorder with a poor, but not hopeless, prognosis. Hematologic
abnormalities in this condition raise the risk of hemorrhage, which may benefit from surgical
intervention. If surgical evacuation is attempted, surgeons should exercise caution when
considering a craniotomy.
Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study.
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